Patents Examined by Leon B. Lankford, Jr.
  • Patent number: 7244552
    Abstract: Artificial dermis (1) obtained from plasma with platelets (2) and human fibroblasts. The plasma with platelets (2) is obtained from the fractionating of total blood (4) from the patient (8) by light centrifugation, and the human fibroblasts (3) from a skin biopsy (5). Clotting is obtained by adding calcium. This artificial dermis (1) provides for the rapid growth of the keratinocytes (6) seeded on its surface to build an artificial skin (7) which can easily be transplanted. Large areas of artificial dermis (1) are obtained from a small skin biopsy (5) and minimal quantities of plasma with platelets (2), which being enriched with cytokines and platelet growth factors, strengthens the proliferation of the cells seeded, both inside and on the surface. The artificial skin (7) obtained can be used to treat major burn treatments, chronic skin ulcers, etc., or be used, by employing genetically altered cells, as a vehicle for gene therapy.
    Type: Grant
    Filed: February 28, 2002
    Date of Patent: July 17, 2007
    Assignees: Centro de Investigaciones Energeticas Medioambientales y Tecnologicas (C.I.E.M.A.T.), Centro Comunitario de Transfusión de Asturias-Cruz Roja Espanola, Fundación Marcelino Botin
    Inventors: Jose Luis Jorcano Noval, Fernando Larcher Laguzzi, Alvaro Meana Infiesta, Sara Gomez Llanes, Marcela Del Rio Nechaevsky
  • Patent number: 7241905
    Abstract: The present invention provides a novel dioxin analogue for use in the search for organisms capable of degrading dioxin.
    Type: Grant
    Filed: March 29, 2001
    Date of Patent: July 10, 2007
    Assignee: Forestry and Forest Products Research Institute
    Inventors: Masaya Nakamura, Shojiro Hishiyama
  • Patent number: 7241612
    Abstract: A biopesticidal composition for controlling insects (e.g., pecan weevils, the diaprepes root weevil, fall armyworm, fire ants), containing an agriculturally acceptable carrier and an effective insect (e.g., pecan weevils, the diaprepes root weevil, fall armyworm, fire ants) biopesticidal amount of a fungus selected from the group consisting of Beauveria bassiana having the identifying characteristics of Beauveria bassiana NRRL 30593, Metarhizium anisopliae having the identifying characteristics of Metarhizium anisopliae NRRL 30594, Beauveria bassiana having the identifying characteristics of Beauveria bassiana NRRL 30601, Beauveria bassiana having the identifying characteristics of Beauveria bassiana NRRL 30600, or mixtures thereof. Also, a method for controlling insects (e.g., pecan weevils, the diaprepes root weevil, fall armyworm, fire ants), involving applying an effective insect biopesticidal amount of the composition to the insects or to the plants, areas or substrates infested with the insects.
    Type: Grant
    Filed: August 14, 2003
    Date of Patent: July 10, 2007
    Assignee: The United States of America, as Represented by the Secretary of Agriculture
    Inventors: David I. Shapiro-Ilan, Wayne A. Gardner, Bruce Wood, James R. Fuxa
  • Patent number: 7238504
    Abstract: Provided is a process for preparing an immobilized enzyme, which comprises the steps of immobilizing an enzyme used for decomposing oil & fat on a carrier, by adsorption, without drying, bringing the immobilized enzyme into contact with a fatty acid triglyceride or fatty acid partial glyceride, or mixtures thereof, and adjusting the moisture content of the enzyme to 5% to 50% by weight based on the weight of the carrier, wherein the enzyme is used for esterification.
    Type: Grant
    Filed: July 1, 2003
    Date of Patent: July 3, 2007
    Assignee: Kao Corporation
    Inventors: Manabu Sato, Masami Shimizu, Minoru Kase, Takaaki Watanabe, Jun Kohori
  • Patent number: 7229826
    Abstract: The present invention concerns methods for the ex vivo formation of mammalian bone and subsequent uses of the bone. A critical and distinguishing feature of the present invention are defined tissue culture conditions and factors resulting in the formation of bone cell spheroids. The invention also provides for methods of implanting into subjects the ex vivo formed bone. Also described are methods for genetically altering the bone cell spheroids to affect bone formation, identification of candidate modulators of bone formation, and identification of genes involved in bone formation.
    Type: Grant
    Filed: June 8, 2004
    Date of Patent: June 12, 2007
    Assignee: The Regents of the University of Michigan
    Inventors: Sujata Kale, Michael W. Long
  • Patent number: 7220779
    Abstract: A pig growth enhancer, which comprises, as an active ingredient, at least one compound selected from 5-aminolevulinic acid, a derivative thereof and a salt thereof, and a method for enhancing pig growth, which comprises administering the growth enhancer to a pig.
    Type: Grant
    Filed: July 23, 2002
    Date of Patent: May 22, 2007
    Assignee: Cosmo Oil Co., Ltd.
    Inventors: Toshio Oshida, Tohru Tanaka
  • Patent number: 7220538
    Abstract: The present invention is directed to nanoparticle compositions for maintaining organ, tissue and cellular viability when such are separated from normal physiological supports. Compositions containing the nanoparticle compositions and methods of preserving organs such as kidneys, both in vivo and ex vivo, are also disclosed.
    Type: Grant
    Filed: May 7, 2004
    Date of Patent: May 22, 2007
    Assignee: Lifeblood Medical, Inc.
    Inventors: Joseph Fischer, Jan Baker, Robert G. L. Shorr
  • Patent number: 7217558
    Abstract: The invention relates to Corynebacterium ammoniagenes CJXOL 0201 KCCM 10447 producing 5?-xanthylic acid. More specifically, the invention relates to Corynebacterium ammoniagenes CJXOL 0201 KCCM 10447 which is a mutant strain of Corynebacterium ammoniagenes KCCM 10340 having a resistance to oligomycin. In order to obtain mutant strain having enhanced respiratory activity, the present invention adopted Corynebacterium ammoniagenes KCCM 10340 as parent strain and treated it with UV radiation and mutation derivatives such as N-methyl-N?-nitro-n-nitrosoguanidine(NTG) according to ordinary procedure. Therefore, Corynebacterium ammoniagenes CJXOL 0201 KCCM 10447 of the present invention makes it possible to increase ATP reproducing activity for same period of fermentation and can accumulate 5?xanthylic acid in culture medium at a high yield and concentration rate.
    Type: Grant
    Filed: December 10, 2003
    Date of Patent: May 15, 2007
    Assignee: CJ Corporation
    Inventors: Young-Hyeon Kwag, Ki-Hoon Oh, Jeong-Hwan Kim, Yoon-Suk Oh, Jae-Ick Sim, Young-Hoon Park, Jea-Young Chang
  • Patent number: 7214481
    Abstract: The invention discloses methods, compositions and kits for stabilizing a solubilized phenyl phosphate, preferably paranitrophenyl phosphate (PNPP), using charcoal. Also disclosed are methods, compositions and kits for recycling solubilized phenyl phosphate, preferably PNPP, that has an absorbance of less than 0.1 when measured at 405 nm due to non-enzymatic hydrolysis.
    Type: Grant
    Filed: November 1, 2005
    Date of Patent: May 8, 2007
    Assignee: BioFX Laboratories, Inc.
    Inventor: Thomas M. Woerner
  • Patent number: 7214792
    Abstract: A novel microorganism producing a nontoxic, non-antigenic exopolysaccharide is taught. The exopolysaccharide has neutral sugars migrating at the same rate as mannose, fucose, fructose and galactose, acidic sugars migrating at the same rate as fucose and amine sugars migrating at the same rate as glucose and fucose, and wherein the ratio of galactose:fucose:glucose:mannose is about 1:2:3:6. The microbe and the exopolysaccharide have uses as a biofilm in geologic applications and have several consumer uses as food and drug polymers and use as a plasma extender.
    Type: Grant
    Filed: October 8, 2003
    Date of Patent: May 8, 2007
    Assignee: The Board of Regents, The University of Texas System
    Inventors: Lee A. Bulla, John P. Turner
  • Patent number: 7211413
    Abstract: Provided are a process for producing purified anthocyanidin glucoside in which a rhamnose end of anthocyanidin rutinoside is cleaved using rhamnosidase to convert the anthocyanidin rutinoside component into anthocyanidin glucoside, the anthocyanidin glucoside component being then purified and isolated; or a crystalline anthocyanidin glucoside salt obtained by further crystallizing the purified anthocyanidin glucoside and a process for producing the same. Also provided are a process for producing purified anthocyanidin rutinoside in which a glucose end of anthocyanidin glucoside is cleaved using ?-glucosidase to degrade and remove the end, the anthocyanidin rutinoside component being then purified and isolated; or a crystalline anthocyanidin rutinoside salt obtained by further crystallizing the purified anthocyanidin rutinoside and a process for producing the same.
    Type: Grant
    Filed: September 11, 2001
    Date of Patent: May 1, 2007
    Assignee: Meiji Seika Kaisha, Ltd.
    Inventors: Hitoshi Matsumoto, Satoshi Hanamura, Masao Hirayama
  • Patent number: 7211650
    Abstract: The present invention provides a method for the part purification of fibrinogen from milk, the method comprising the transfer of protease enzyme which is present in the milk, into the whey phase with the removal or partition if fibrinogen into another phase of the milk. The present invention also provides a method for obtaining fibrinogen from a fluid, the method comprising: a) contacting the fluid with a hydrophobic interaction chromatography resin under conditions where the fibrinogen binds to the resin; and b) removing the bound protein by means of elution.
    Type: Grant
    Filed: March 22, 2001
    Date of Patent: May 1, 2007
    Assignee: Pharming Intellectual Property BV
    Inventors: Graham McCreath, Udell Michael
  • Patent number: 7205133
    Abstract: Provided is a process for producing acrylamide with good storage stability and improved acrylamide polymer physical properties using a microbial catalyst. A microbial catalyst having catalytic activity to convert from acrylonitrile to acrylamide is washed with an aqueous acrylic acid solution, and then the washed microbial catalyst is used for the conversion reaction, so that the production of the above acrylamide is achieved.
    Type: Grant
    Filed: March 27, 2002
    Date of Patent: April 17, 2007
    Assignee: Dia-Nitrix Co., Ltd.
    Inventors: Hiroyasu Banba, Natsuko Morooka
  • Patent number: 7202063
    Abstract: A process for producing rhamnolipids involving culturing Pseudomonas chlororaphis strain NRRL B-30761 in a first aqueous culture medium containing about 0.3% NH4H2PO4, about 0.2% K2HPO4, about 0.2% carbon source, about 0.5 mg/L FeSO4, and about 0.1% MgSO4 for about 24–about 48 hours at about 25°–about 30° C. with orbital shaking, and then culturing Pseudomonas chlororaphis strain NRRL B-30761 in a static second aqueous culture medium containing per liter about 2% carbon source, about 0.7 g KH2PO4, about 0.9 g Na2HPO4, about 2 g NaNO3, about 0.4 g MgSO4.7H2O, and about 0.1 g CaCl2.2H2O for at least about 72 hours at about 20°–about 23° C., wherein the first and second aqueous culture medium contains only one source of carbon.
    Type: Grant
    Filed: August 3, 2005
    Date of Patent: April 10, 2007
    Assignee: United States of America as represented by the Secretary of Agriculture
    Inventors: Nereus W. Gunther, Daniel K. Y. Solaiman, William F. Fett
  • Patent number: 7202212
    Abstract: The present invention provides both a method and means for regulating I?B? degradation, NF?B activity, and NF?B-dependent gene expression within living cells, tissues, and organs in-situ. The selective regulation is performed using native PR-39 peptide or one of its shorter-length homologs, for interaction with such I?B? and proteasomes as are present in the cytoplasm of viable cells. The result of PR-39 peptide interaction with I?B? is a selective alteration in the intracellular proteolytic activity of proteasomes, which in turn, causes a reduction of I?B?, a decrease of NF?B activity, and a down-regulation of NF?B-dependent gene expression.
    Type: Grant
    Filed: March 18, 2003
    Date of Patent: April 10, 2007
    Assignee: Beth Israel Deaconess Medical Center
    Inventors: Michael Simons, Youhe Gao
  • Patent number: 7198907
    Abstract: The invention concerns a culture medium for isolating Vibrio bacteria, characterised in that it comprises, in a Vibrio culture medium, at least a chromogenic agent selected among the ?-glucosidase substrates and the ?-galactosidase substrates.
    Type: Grant
    Filed: June 27, 2001
    Date of Patent: April 3, 2007
    Inventor: Alain Rambach
  • Patent number: 7198785
    Abstract: The present invention generally relates to the treatment of uremic toxins in vivo using uremic toxin-treating enzymes, and/or cells capable of producing uremic toxin-treating enzymes or otherwise reacting with uremic toxins. Non-limiting examples of cases where the treatment of uremic toxins is desired include renal disease or dysfunction, gout, subjects receiving chemotherapy, or the like. In one aspect, the treatment includes an oral delivery composition able to reduce the blood concentration of one or more non-protein nitrogen compounds in vivo. The composition, in some cases, may comprise one, two, or more uremic toxin-treating enzymes, such as urease, uricase or creatininase. The oral delivery composition may be able to deliver the uremic toxin-treating enzymes, substantially undigested, to the intestines, where the enzymes can interact with uremic toxins transported to the intestines from the bloodstream.
    Type: Grant
    Filed: December 9, 2003
    Date of Patent: April 3, 2007
    Assignee: Brown University
    Inventors: Jill A. O'Loughlin, Jan Markus Bruder, Michael J. Lysaght
  • Patent number: 7198947
    Abstract: The present invention provides a method for production of functional proteins including hormones by renal cells in a three dimensional co-culture process responsive to shear stress using a rotating wall vessel. Natural mixture of renal cells expresses the enzyme 1-a-hydroxylase which can be used to generate the active form of vitamin D: 1,25-diOH vitamin D3. The fibroblast cultures and co-culture of renal cortical cells express the gene for erythropoietin and secrete erythropoietin into the culture supernatant. Other shear stress response genes are also modulated by shear stress, such as toxin receptors megalin and cubulin (gp280). Also provided is a method of treating in-need individual with the functional proteins produced in a three dimensional co-culture process responsive to shear stress using a rotating wall vessel.
    Type: Grant
    Filed: December 11, 2003
    Date of Patent: April 3, 2007
    Assignee: The United States of America as represented by the Administrator of the National Aeronautics and Space Administration
    Inventors: Thomas John Goodwin, Timothy Grant Hammond, James Howard Kaysen
  • Patent number: 7198945
    Abstract: A cell in which a reaction product of a substance to be modified and an amphipathic compound is non-covalently bound to a cell membrane, wherein said compound has the following features: (1) having one or more aliphatic hydrocarbon groups at one end; (2) having one or more portions containing a hydrophilic group in a molecule; and (3) having one or more reactive functional groups which are capable of covalently binding with the substance to be modified at an end different from the end in the above (1).
    Type: Grant
    Filed: August 5, 2002
    Date of Patent: April 3, 2007
    Assignees: Teruyuki Nagamune, NOF Corporation
    Inventors: Teruyuki Nagamune, Chika Itoh, Tohru Yasukohchi, Syunsuke Ohhashi, Kazuhiro Kubo
  • Patent number: 7195071
    Abstract: This invention relates to enzyme compositions and methods of using these enzyme compositions, inter alia, to degrade succinoglycan. In one embodiment, the present invention provides a method of degrading succinoglycan comprising contacting the succinoglycan with an enzyme composition that comprises enzymes that are capable of degrading the linkages between sugar moieties of the succinoglycan.
    Type: Grant
    Filed: August 5, 2003
    Date of Patent: March 27, 2007
    Assignee: Halliburton Energy Services, Inc.
    Inventors: Ronald J. Powell, Bradley L. Todd